"Verification of the findings by other means, such as SOC imaging, was further complicated by the very nature of the trial, which specifically enrolled patients who were negative or equivocal on all available SOC imaging. These inherent challenges led to a high number of lesions not being confirmed as true-positives in the study. However, the fact that prostate cancer was confirmed in all 64Cu-SAR-Bombesin PET-positive lesions that were biopsied strongly reinforces the potential clinical value of this agent and the need it may fulfill within the current diagnostic landscape."
"Verification of the findings by other means, such as SOC...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$2.24 |
Change
0.010(0.45%) |
Mkt cap ! $719.8M | |||
| Open | High | Low | Value | Volume |
| $2.30 | $2.37 | $2.21 | $6.293M | 2.748M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5025 | $2.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.26 | 17072 | 2 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| CU6 (ASX) Chart |